{"abstract": "Novartis, the Swiss pharmaceuticals maker, said Wednesday that it would buy the biopharmaceutical company Corthera for $120 million, giving it the right to develop a new drug against heart failure.", "web_url": "https://dealbook.nytimes.com/2009/12/24/novartis-to-buy-us-firm-corthera-for-120-million/", "snippet": "Novartis, the Swiss pharmaceuticals maker, said Wednesday that it would buy the biopharmaceutical company Corthera for $120 million, giving it the right to develop a new drug against heart failure.", "lead_paragraph": "Swiss pharmaceuticals maker Novartis said Wednesday it will buy U.S. biopharmaceutical company Corthera for $120 million, giving it the right to develop a new drug against heart failure.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Novartis to Pay $120 Million for Corthera\u2019s Biotech", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 2, "major": "N"}], "pub_date": "2009-12-24T09:15:19+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/e905a189-0edd-5ddd-a048-946b04f07f6d", "word_count": 179, "uri": "nyt://article/e905a189-0edd-5ddd-a048-946b04f07f6d"}